a memorandum of understanding between mei'an pharmaceutical and legacy health care, a swiss botanical drug research and development company
publisher:maxhealth date:2017-5-30
in may 2017, the company signed a memorandum with legacy health care, a swiss botanical drug research and development company, to operate its plant extract related products in mainland china and macao in the form of a joint venture company established in china and controlled by the company and patented by the other party. the product is currently licensed to operate in the european, american and southeast asian markets (including hong kong and taiwan) under nestle health care's goldman and abbott respectively.
[] []
